Cleavable Linker Conjugates for Selective Tumor Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for conjugates with β-glucuronidase-cleavable linkers that can selectively deliver a drug to a biological target and have favorable physicochemical properties, including solubility and lipophilicity, for the treatment of diseases such as cancer.
Innovation Solution
The development of conjugates comprising a cleavable linker system, specifically a conjugate of Formula (IC) Ab-(G A< -J A< -D C< ) k, which includes enzymatic cleavage to release a free drug like exatecan, exhibiting improved efficacy and physical properties such as higher stability, solubility, permeability, and reduced toxicity profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a cleavable linker system is used to selectively deliver drug to biological target, then therapeutic efficacy is improved, but off-target toxicity occurs
Solution Approach 1:
The patent employs a cleavable linker as an intermediary component between the antibody and drug. This linker is designed to be stable in circulation (preventing off-target toxicity) but cleavable by specific enzymes (β-glucuronidase, cathepsin B) at the tumor site (enabling therapeutic efficacy). The linker acts as a controlled-release mechanism that mediates between the non-toxic antibody carrier and the potent cytotoxic drug.
2Stability of the object's composition
If conjugate structure is optimized for stability, then colloidal stability improves, but solubility and lipophilicity balance becomes challenging
Solution Approach 1:
The patent systematically varies key parameters of the conjugate structure including the number of glycine units (n), the number of drug-antibody conjugates per antibody (k), and the specific linker chemistry. These parameter changes allow optimization of the balance between colloidal stability (requiring sufficient hydrophobic interactions) and solubility (requiring sufficient hydrophilic character). For example, adjusting n in the glycine linker provides fine-tuned control over the hydrophobic-hydrophilic balance.
3Measurement precision
If enzymatic cleavage is designed for specific enzyme recognition, then selective drug release is improved, but enzyme availability at target site varies
Solution Approach 1:
The patent designs the cleavable linker to recognize and be cleaved by multiple enzymes including β-glucuronidase, cathepsin B, and other lysosomal proteases. This multi-enzyme recognition capability provides universality, ensuring that the conjugate can be activated at tumor sites regardless of which specific enzyme is most abundant. The linker sequence is engineered to contain recognition motifs for multiple enzymes, making the system adaptable to variations in enzyme availability across different tumor types and patients.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The conjugates demonstrate enhanced therapeutic efficacy and favorable metabolic profiles, making them suitable for cancer treatment with improved stability and reduced off-target toxicity.
Implementation Method 1
WO 2007011968 and WO 2015182984 disclose certain antibody drug conjugates comprising β-glucuronidase-cleavable linkers. Conjugates of Formula (IC) may undergo enzymatic cleavage to release a free drug (exatecan).
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 3
AI summary
The specification relates to conjugates comprising a linker of Formula (ICA) and pharmaceutically acceptable salts thereof. The specification also relates the use of the conjugates for the treatment of diseases such as cancer, and intermediates useful for the synthesis of the conjugates.